Janus kinase 2 (JAK2) inhibitors in the treatment of multiple myeloma: modulating the myeloma immune microenvironment

被引：4
|
作者：
Giles, Hannah [1 ]
Pratt, Guy [1 ]
机构：
[1] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 192卷 / 03期
关键词：
JAK2; inhibitors; multiple myeloma; myeloma immune; microenvironment; FUNCTION IN-VITRO; CELL-FUNCTION; RUXOLITINIB; TOFACITINIB; EFFICACY; DISEASE;
D O I：
10.1111/bjh.17277
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：420 / 422
页数：3
相关论文
共 50 条
  • [1] Oncostatin M induces association of GRB2 with Janus kinase JAK2 in multiple myeloma cells.
    Chauhan, D
    Kharbanda, S
    Ogata, A
    Urashima, M
    Frank, D
    Malik, N
    Kufe, D
    Anderson, K
    BLOOD, 1995, 86 (10) : 214 - 214
  • [2] Janus Kinase 2 (JAK2) Inhibitors for the Treatment of Myeloproliferative Neoplasm (MPN)
    Purandare, Ashok V.
    Lorenzi, Matthew V.
    Lombardo, Louis J.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 45, 2010, 45 : 211 - 227
  • [3] ONCOSTATIN-M INDUCES ASSOCIATION OF GRB2 WITH JANUS KINASE JAK2 IN MULTIPLE-MYELOMA CELLS
    CHAUHAN, D
    KHARBANDA, SM
    OGATA, A
    URASHIMA, M
    FRANK, D
    MALIK, N
    KUFE, DW
    ANDERSON, KC
    JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (06): : 1801 - 1806
  • [4] Anti-Myeloma Effects of the Janus Kinase 2 (JAK2) Inhibitor SAR503 Alone and in Combination Treatment
    Chen, Haiming
    Li, Mingjie
    Li, Jennifer
    Delijani, Kevin
    Rauch, Danielle
    DeCorso, Kevin
    Prajogi, Andrew
    Wang, Cathy S.
    Sanchez, Eric
    Bonavida, Benjamin
    Berenson, James R.
    BLOOD, 2012, 120 (21)
  • [5] Multiple Myeloma and the Immune Microenvironment
    Kawano, Yawara
    Roccaro, Aldo M.
    Ghobrial, Irene M.
    Azzi, Jamil
    CURRENT CANCER DRUG TARGETS, 2017, 17 (09) : 806 - 818
  • [6] The Role of JAK Inhibitors in Multiple Myeloma
    Ghermezi, Matthew
    Spektor, Tanya M.
    Berenson, James R.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (09) : 500 - 505
  • [7] Screening of JAK2 V617F mutation in multiple myeloma
    A Fiorini
    G Farina
    G Reddiconto
    M Palladino
    E Rossi
    T Za
    L Laurenti
    S Giammarco
    P Chiusolo
    G Leone
    S Sica
    Leukemia, 2006, 20 : 1912 - 1913
  • [8] Screening of JAK2 V617F mutation in multiple myeloma
    Fiorini, A.
    Farina, G.
    Reddiconto, G.
    Palladino, M.
    Rossi, E.
    Za, T.
    Laurenti, L.
    Giammarco, S.
    Chiusolo, P.
    Leone, G.
    Sica, S.
    LEUKEMIA, 2006, 20 (10) : 1912 - 1913
  • [9] The immune microenvironment and immunotherapies in multiple myeloma
    Gazeau, Nicolas
    Manier, Salomon
    HEMATOLOGIE, 2020, 26 : 4 - 11
  • [10] Advances in the design and discovery of next-generation janus kinase-2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasms
    Daoud, Safa
    Taha, Mutasem Omar
    EXPERT OPINION ON DRUG DISCOVERY, 2024, 19 (12) : 1403 - 1415
12345